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We combined information published worldwide on the seroprevalence of hepatitis B surface antigen (HbsAg) and antibodies against
hepatitis C virus (anti-HCV) in 27881 hepatocellular carcinomas (HCCs) from 90 studies. A predominance of HBsAg was found in
HCCs from most Asian, African and Latin American countries, but anti-HCV predominated in Japan, Pakistan, Mongolia and Egypt.
Anti-HCV was found more often than HBsAg in Europe and the United States.
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Hepatocellular carcinoma (HCC) represents approximately 6% of
all new cancer cases diagnosed worldwide, with more than half of
these occurring in China alone (Parkin et al, 2005). Relatively high
incidence rates are also found in South Eastern Asia and in sub-
Saharan Africa (Parkin et al, 2005). One of the least curable
malignancies, HCC is the third most frequent cause of cancer death
among men worldwide (Parkin et al, 2005).
Chronic infection with hepatitis B virus (HBV) and hepatitis C
virus (HCV) are the most important causes of HCC (IARC, 1994).
According to the World Health Organisation (WHO), approxi-
mately 350 million people are chronically infected with HBV
(WHO, 2004) and 170 million with HCV (WHO and the Viral
Hepatitis Prevention Board, 1999) worldwide. There are no
comparable statistics for the number of individuals coinfected
with both HBV and HCV.
The relative importance of HBV and HCV infections in HCC
aetiology is known to vary greatly from one part of the world to
another (Parkin, 2006), and can change over time (Lu et al, 2006).
In order to investigate this issue, we collated all published data
on the prevalence of chronic HBV and HCV infection among
HCC cases.
MATERIALS AND METHODS
MEDLINE and WHO regional indexed databases were used to
search for articles published from 1 January 1989 (after HCV
testing became available) to 31 October 2006, by means of the
MeSH terms: ‘hepatocellular carcinoma’, ‘hepatitis B virus’ and
‘hepatitis C virus or hepacvirus’. Additional relevant studies
were identified in the reference lists of selected articles. No
language limitation was imposed. Eligible studies had to report
prevalence of both hepatitis B surface antigen (HBsAg) and
antibodies against HCV (anti-HCV), alone and in combination, for
at least 20 HCC cases. To avoid multiple inclusions of the same
HCC cases in more than one article, the time and place of
recruitment of cases were cross-checked and the most recent
publication was used. In the event that study methods indicated
the availability of HBsAg and anti-HCV prevalence data but did
not report both of them and the percent of coinfection in the
article, authors were contacted for the supplementary information.
In the course of contacting authors, additional data became
available from one study expanded since the original publication
(Appendix A).
The key information extracted from each study were study
country, gender distribution, generation of HCV serology tests
used, prevalence of HBsAg alone (HBsAg
þ) and anti-HCV alone
(anti-HCV
þ) and in combination (HBV/HCV coinfection),
and the number of cases that were seronegative for both viral
markers.
Key information on 110 selected studies is given in the Appendix
A by continent and country. For multicentric studies, HBsAg
þ
and anti-HCV
þ prevalence data were separated by country
(Appendix A). Study size varied substantially and four reports
(one each from China, Japan, Taiwan and the United States)
included more than 1000 HCC cases. With respect to anti-HCV
testing, 17 studies (published from 1989 to 1994) reported the
use of first-generation enzyme-linked immunoabsorbant assay
(ELISA), 29 studies (published from 1992 to 2003) second-
generation ELISA and 42 studies (published from 1997 to 2006)
third-generation ELISA. Nineteen studies did not report the
generation of HCV testing used; four of these were assumed
to have used first-generation ELISA based on date of publication
or patient admission. Studies known or likely to have used
first-generation ELISA were not included in the computation of
HCV prevalence owing to known problems of sensitivity and
specificity of those assays (Booth et al, 2001). Two studies used
HCV RNA instead of anti-HCV, and were included in the analysis
(Appendix A).
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After exclusion of studies using first-generation ELISA for anti-
HCV testing, there were 90 studies with relevant data on the
prevalence of HBsAg and anti-HCV, covering 27881 HCC cases
from 36 countries (Table 1). The majority of cases were from Asia
(66%) followed by the Americas (15%), Europe (12%) and Africa
(7%). In Figures 1–3, HBsAg
þ and anti-HCV
þ prevalence data
are shown for countries with information on at least 150 HCC
cases. Otherwise countries from the same continent were
combined. Substantial variations in HBsAg and anti-HCV
prevalence were observed between countries and continents.
Asia
The largest number of HCC cases from any single country in Asia
came from Taiwan, with 8595 HCC cases identified from a single
multicentre study (Lu et al, 2006), Japan and China (Figure 1). The
proportion of HBsAg
þ HCC cases was greater than 50% in China,
Taiwan, Korea, Thailand, Vietnam and Turkey. The lowest
proportion of HBsAg
þ HCC cases was reported in Japan where
there was a strong predominance of anti-HCV seropositivity in
HCC cases (68%). A higher proportion of anti-HCV
þ than
HBsAg
þ HCC cases was also found in Pakistan (45%), and in
Mongolia (40%), where HBV/HCV coinfection was also very
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Figure 1 Seroprevalence and corresponding 95% confidence intervals of HBsAg, anti-HCV, both and negative in patients with HCC in Asia.
*Indonesia,
Myanmar, Iran, Lebanon and Saudi Arabia.
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combination with HBsAg than alone. The highest proportion of
HCC cases seronegative for both hepatitis viruses was found in
India (37%).
Europe
The countries in Europe where the largest numbers of HCC cases
were studied were Italy, Greece and Germany (Figure 2). The
proportion of HBsAg
þ HCC cases (56%) was higher than that of
anti-HCV
þ HCC in Greece, whereas the opposite was observed
everywhere else in Europe. In Italy and Spain, the proportions of
anti-HCV
þ HCC cases were 43 and 48%, respectively. Seroposi-
tivity for anti-HCV was significantly higher than for HBsAg also in
Austria and Sweden, whereas in Germany the seroprevalence of the
two viruses was similar. Hepatitis B virus/HCV coinfection was
rare in most European studies, whereas HCC cases seronegative for
both hepatitis viruses were relatively common, measuring over
80% in Sweden.
The Americas
A majority of American studies on HCC and hepatitis viruses were
conducted in the United States (Figure 3), with two-thirds of HCC
cases coming from a nation-wide linkage study for the Surveillance
Epidemiology and End-Results Program. In the United States, 9%
of HCC cases were HBsAg
þ and 22% were anti-HCV
þ. The
Table 1 Continent-specific distribution of studies with HCC cases
a
Continent No. of studies HCC cases Countries represented
Asia 47 18400 China, India, Indonesia, Iran, Japan, Korea, Lebanon, Mongolia, Myanmar,
Pakistan, Saudi Arabia, Taiwan, Thailand, Turkey and Vietnam
Europe 22 3469 Austria, Belgium, Germany, Greece, Italy, Sweden, Spain and UK
Americas 12 4148 United States, Brazil, Peru and Mexico
Africa 12 1864 Egypt, Gambia, Mozambique, Niger, Nigeria, Senegal, South Africa,
Somalia and Sudan
Total 90
b 27881
aStudies that used first-generation ELISA for anti-HCV detection were excluded.
bTotal does not add up to 90 owing to three multi-continent studies.
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Figure 2 Seroprevalence and corresponding 95% confidence intervals of HBsAg, anti-HCV, both and negative in patients with HCC in Europe.
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high proportion (67%) of HCC cases were seronegative for
markers of both hepatitis viruses. In Brazil, 37 and 18% of HCC
cases were HBsAg
þ and anti-HCV
þ, respectively. Only 207
additional HCC cases were available from other American
countries (Peru and Mexico), where prevalence of HBsAg exceeded
that of anti-HCV.
Africa
Nearly half of the data on HCC in Africa came from Egypt
(Figure 3), where a very high proportion (69%) of HCC cases was
anti-HCV
þ. All other African countries showed a preponderance
of HBsAg seropositivity. HBV/HCV coinfection did not exceed
10% anywhere in Africa, whereas approximately 30% of HCC cases
were seronegative for both hepatitis viruses in South Africa and
Mozambique.
DISCUSSION
This review, based on nearly 30000 HCC cases, confirms
wide international variation in the relative importance of HBV
and HCV in this disease. As expected, HBV infection was found
substantially more often than HCV infection in HCC cases from
the majority of Asian and African countries with the available data.
Conversely, more HCC cases were found to be anti-HCV
þ than
HBsAg
þ in Europe and in the United States, as was also the case in
Japan, Pakistan and Mongolia, and in Asia generally. In some
countries (i.e., China and Mongolia), more than 10% of HCC cases
were coinfected with both hepatitis viruses, thus hampering the
attribution of a fraction of HCC cases to HBV or HCV.
More than half of HCC cases were both HBsAg
  and anti-HCV
 
in the United States and some North European countries, thus
pointing to the relative importance of heavy alcohol consumption
and, possibly, smoking, obesity and diabetes mellitus (Yuan et al,
2004) in areas where hepatitis virus prevalence and HCC incidence
are low.
Our systematic review failed to identify information on HBV
and HCV infection among HCC cases in Eastern Europe, Russia,
Central Asia and the majority of African and Latin American
countries. None of the studies we found from Oceania using
second- or third-generation ELISA met our inclusion criteria.
However, a record-linkage study from New South Wales, Australia
showed a similar proportion of HBsAg
þ (45%) and anti-HCV
þ
(53%) HCCs and low frequency of HBV/HCV coinfection (2%)
among 281 virus-related HCC cases (Amin et al, 2006).
In addition to lack of data from many parts of the world, some
weaknesses of our present review should be borne in mind. The
extent to which the HCC cases we reported upon are representa-
tive, at a national level, is unclear, especially where only small
studies were available. Furthermore, important secular trends
may be concealed by our analysis, as in the largest study identified
(Lu et al, 2006), which showed a steady increase in the proportion
of HCC cases related to HCV in the last two decades in Taiwan.
The vast majority of studies did not provide information on
occult HBV infection. Occult HBV infection seems, however, to
have little or no clinical significance, at least among immuno-
competent individuals (Knoll et al, 2006). Most importantly,
owing to the long latent period of HCC, seropositivity among HCC
cases does not reflect the current importance of the two viruses in
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Figure 3 Seroprevalence and corresponding 95% confidence intervals of HBsAg, anti-HCV, both and negative in patients with HCC in the Americas and
Africa.
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earlier.
Based upon prevalence of the infections in different popula-
tions around the world and a relative risk of 20 for both
viruses, Parkin (2006) estimated the fraction of HCC attribu-
table to HBV and HCV in 2002 to be, respectively, 23 and 20%
in developed countries and 59 and 33% in developing countries.
Our simpler approach, based on HCC cases only, was mainly
dictated by the wish to use information from many world
populations for whom information on HCC was available
but not data on population prevalences of HBV and HCV. It
suggests, however, that the relative contribution of HCV to the
current HCC burden in middle-aged and old individuals in
developed countries and in some developing countries might be
higher than in Parkin (2006). In fact, seroprevalence surveys on
which attributable risks are based tend to over-sample young
individuals at low risk of HCV infection (e.g., blood donors and
pregnant women, WHO, 1999; Madhava et al, 2002). In conclusion,
our findings underline the importance of the prevention of HCV
infection that, in the absence of a vaccine, will require an
integrated strategy including screening of blood donations, safe
injection practices and avoidance of unnecessary injections
(Ahmad, 2004).
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Ding X
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Tanioka H J Infect Chemother 2002; 8: 64–69 Japan 1019 709 310 16.4 72.6 0.9 10.1
Fukuhara T J Radiat Res (Tokyo) 2001; 42: 117–130 Japan 168 — — 21.4 36.3 11.3 31.0
Koike Y Hepatology 2000; 32: 1216–1223 Japan 236 164 72 9.7 79.7 0.4 10.2
Abe K Hepatology 1998; 28: 568–572 Japan 122 89 33 18.0 61.5 4.9 15.6
Tanaka K J Natl Cancer Inst 1996; 88: 742–746 Japan 91 73 18 18.7 75.8 2.2 3.3
Shiratori Y Hepatology 1995; 22: 1027–1033 Japan 205 163 42 11.2 83.4 1.0 4.4
Suga M Hepatogastroenterology 1994; 41: 438–441 Japan 63 51 12 27.0 54.0 9.5 9.5
Eto H Southeast Asian J Trop Med Public
Health 1994; 25:8 8–9 2
Japan 89 69 20 23.6 65.2 3.4 7.9
Kiyosawa K
a Cancer Chemother Pharmacol 1992; 31 Japan 162 — — 13.0 77.8 3.1 6.2
(Suppl): S150–S156 267 225 42 30.7 59.6 1.5 8.2
112 94 18 53.6 33.9 4.5 8.0
Yuki N
a Dig Dis Sci 1992; 37: 65–72 Japan 148 126 22 17.6 61.5 8.1 12.8
Nishioka K
b Cancer 1991; 67: 429–433 Japan 180 — — 35.6 44.4 6.1 13.9
Saito I
a Proc Natl Acad Sci 1990; 87: 6547–6549 Japan 253 207 46 19.4 53.8 0.8 26.1
Ding X
c Jpn J Inf Dis 2003; 56: 19–22 Korea 55 42 13 69.1 5.5 3.6 21.8
Kwon SY J Gastroenterol Hepatol 2000; 15: 1282–1286 Korea 26 — — 61.5 15.4 0.0 23.1
Abe K Hepatology 1998; 28: 568–572 Korea 55 42 13 81.8 5.5 3.6 9.1
Shin HR Int J Epidemiol 1996; 25: 933–940 Korea 170 — — 65.3 10.0 1.2 23.5
Park BC J Viral Hepat 1995; 2: 195–202 Korea 540 431 109 58.1 11.3 3.0 27.6
Pyong SJ
a Jpn J Cancer Res 1994; 85: 674–679 Korea 90 68 22 15.6 73.3 1.1 10.0
Yaghi C World J Gastroenterol 2006; 2: 3575–3580 Lebanon 92 78 14 64.1 16.3 3.3 16.3
Tsatsralt-Od B
c J Med Virol 2005; 77: 491–499 Mongolia 76 46 30 17.1 14.5 68.4 0
Shizuma T Kansenshogaku Zasshi 2005; 79: 824–825 Mongolia 90 — — 34.4 48.9 5.6 11.1
Oyunsuren T Asian Pac J Cancer Prev 2006; 7: 460–462 Mongolia 197 110 87 30.3 39.7 25.1 5.0
Nakai K J Clin Microbiol 2001; 39: 1536–1539 Myanmar 25 — — 56.0 24.0 12.0 8.0
Hamza H Proc World Congress of Epidemiology 2005 Pakistan 57 40 17 21.1 43.9 7.0 28.1
Khokhar N J Ayub Med Coll Abbottabad 2003; 15: 1–4 Pakistan 57 45 12 15.8 47.4 3.5 33.3
Sharieff S Trop Doct 2001; 31: 224–225 Pakistan 201 149 52 35.8 41.3 7.0 15.9
Mumtaz MS J Rawal Med Coll 2001; 5: 78–80 Pakistan 44 — — 25.0 54.5 6.8 13.6
Kausar S Pak J Gastroenterol 1998; 12: 1–2 Pakistan 30 — — 16.7 73.3 6.7 3.3
Butt AK J Pak Med Assoc 1998; 48: 197–201 Pakistan 76 65 11 10.5 75.0 10.5 3.9
Abdul Mujeeb S Trop Doct 1997; 27: 45–46 Pakistan 54 — — 42.6 9.3 24.1 24.1
Tong CY Epidemiol Infect 1996; 117: 327–332 Pakistan 23 22 1 78.3 4.3 4.3 13.0
Ayoola EA J Gastroenterol Hepatol 2004; 19: 665–669 Saudi Arabia 118 96 22 63.6 8.5 3.4 24.6
Al Karawi MA
a J Gastroenterol Hepatol 1992; 7: 237–239 Saudi Arabia 42 38 4 33.3 26.2 4.8 35.7
Khan LA Saudi Med J 2001; 22: 641–642 Saudi Arabia 24 23 1 20.8 25.0 4.2 50.0
Ozer B Turk J Gastroenterol 2003; 14: 85–90 Turkey 35 28 7 65.7 28.6 2.9 2.9
Uzunalimoglu O Dig Dis Sci 2001; 46: 1022–1028 Turkey 207 163 44 52.2 19.3 3.9 24.6
Lu SN Int J Cancer 2006; 119: 1946–1952 Taiwan 8595 6741 1854 53.2 27.9 8.3 10.7
Tangkijvanich P J Gastroenterol 1999; 34: 227–233 Thailand 86 69 17 58.1 10.5 8.1 23.3
Tangkijvanich P J Gastroenterol 2003; 38: 142–148 Thailand 101 86 15 56.4 5.0 8.9 29.7
Songsivilai S Trans R Soc Trop Med Hyg 1996;
90: 505–507
Thailand 80 — — 60.0 10.0 3.8 26.2
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Cases Prevalence (%)
First author Reference Country Total Male Female HBsAg
+ Anti-HCV
+
HBsAg
+
Anti-HCV
+
HBsAg
 
anti HCV
 
Ding X
c Jpn J Inf Dis 2003; 56: 19–22 Vietnam 38 30 8 60.5 2.6 0 36.8
Cordier S Int J Cancer 1993; 55: 196–201 Vietnam 149 149 0 92.6 2.0 0 5.4
Continent subtotal 20194 48.1 29.2 7.9 14.8
EUROPE
Schoniger-Hekele M Gut 2001; 48: 103–109 Austria 245 187 58 9.8 36.7 1.6 51.8
Van Roey G Eur J Gastroenterol Hepatol 2000;
12:6 1–6 6
Belgium 124 — — 21.0 23.4 16.9 38.7
Nalpas B
b J Hepatol 1991; 12: 70–74 France 47 — — 6.4 42.6 19.1 31.9
Erhardt A Dtsch Med Wochenschr 2002; 127:
2665–2668
Germany 192 — — 21.4 34.9 4.7 39.1
Rabe C World J Gastroenterol 2001; 7: 208–215 Germany 85 64 21 29.4 24.7 7.1 38.8
Hellerbrand C Dig Dis 2001; 19: 345–51 Germany 118 94 24 7.6 19.5 0.0 72.9
Kubicka S Liver 2000; 20: 312–318 Germany 268 214 54 25.0 16.8 10.1 48.1
Petry W Z Gastroenterol 1997; 35: 1059–1067 Germany 55 — — 20.0 52.7 0.0 27.3
Goeser T Cancer Epidemiol Biomarkers Prev 1994;
3: 311–315
Germany 81 66 15 27.2 24.7 1.2 46.9
Raptis I J Viral Hepat 2003; 10: 450–454 Greece 306 265 41 52.3 21.9 0.7 25.2
Kuper HE Cancer Causes Control 2000; 11: 171–175 Greece 333 283 50 59.5 12.3 3.3 24.9
Hadziyannis S Int J Cancer 1995; 60: 627–631 Greece 65 49 16 56.9 7.7 4.6 30.8
Kaklamani E
a JAMA 1991; 265:1974–1976 Greece 185 166 19 22.7 15.7 23.2 38.4
Franceschi S Cancer Epidemiol Biomarkers Prev 2006;
15: 683–689
Italy 229 183 46 10.0 61.1 3.9 24.9
Donato F Oncogene 2006; 25: 3756–3770 Italy 583 — — 19.7 37.9 2.7 39.6
Ricci G Cancer Lett 1995; 98: 121–125 Italy 104 — — 31.7 20.2 34.6 13.5
Stroffolini T J Hepatol 1992; 16: 360–363 Italy 65 47 18 16.9 58.5 7.7 16.9
Simonetti RG
a Ann Intern Med 1992; 116: 97–102 Italy 212 161 51 7.1 62.7 8.5 21.7
Levrero M
b J Hepatol 1991; 12: 60–63 Italy 167 135 32 22.8 49.1 9.0 19.2
Colombo M
a Lancet 1989; 2: 1006–1008 Italy 132 115 17 14.4 48.5 16.7 20.5
Ladero JM Eur J Cancer 2006; 42: 73–77 Spain 184 150 34 4.9 63.0 1.6 30.4
Rodriguez Vidigal FF An Med Interna 2005; 22: 162–166 Spain 42 37 5 11.9 42.9 0.0 45.2
Ding X
c Jpn J Inf Dis 2003; 56: 19–22 Spain 57 45 12 38.6 12.3 3.5 45.6
Crespo J Med Clin (Barc) 1996; 106: 241–245 Spain 94 82 12 18.1 43.6 10.6 27.7
Bruix J
a Lancet 1989; 2: 1004–1006 Spain 96 67 29 4.2 69.8 5.2 20.8
Widell A Scand J Infect Dis 2000; 32: 147–152 Sweden 95 — — 5.3 16.8 0 77.9
Kaczynski J Scand J Gastroenterol 1996; 31: 809–813 Sweden 64 48 16 0 10.9 0 89.1
Haydon GH Gut 1997; 40: 128–132 United Kingdom 80 — — 16.3 27.5 2.5 53.8
Continent subtotal 4308 23.1 34.3 6.5 36.1
AFRICA
Ezzat S
d Int J Hyg Environ Health 2005;
208: 329–339
Egypt 450 — — 3.8 82.0 5.3 8.9
Abdel–Wahab M Hepatogastroenterology 2000; 47: 663–668 Egypt 385 — — 14.5 61.0 7.0 17.4
Hassan MM J Clin Gastroenterol 2001; 33: 123–126 Egypt 33 23 10 12.1 72.7 3.0 12.1
Darwish MA J Egypt Public Health Assoc 1993; 68: 1–9 Egypt 70 57 13 21.4 30.0 40.0 8.6
Kirk GD Hepatology 2004; 39: 211–219 Gambia 186 — — 59.1 15.1 3.8 22.0
Dazza MC Am J Trop Med Hyg 1993; 48: 237–242 Mozambique 178 141 37 64.6 4.5 1.7 29.2
Cenac A Am J Trop Med Hyg 1995; 52: 293–296 Niger 26 19 7 57.7 7.7 15.4 19.2
Olbuyide IO Trans R Soc Trop Med Hyg 1997; 91: 38–41 Nigeria 64 42 22 48.4 7.8 10.9 32.8
Kew MC Gastroenterology 1997; 112: 184–187 South Africa 231 201 30 44.6 16.9 8.7 29.9
Ka MM Dakar Med 1996; Spec No: 59–62 Senegal 64 56 8 34.4 64.1 1.6 0
Bile K Scand J Infect Dis 1993; 25: 559–564 Somalia 62 53 9 37.1 35.5 4.8 22.6
Omer RE Trans R Soc Trop Med Hyg 2001; 95: 487–491 Sudan 115 88 27 41.7 10.4 0.9 47.0
Continent subtotal 1864 30.0 43.2 6.8 20.0
NORTH AMERICA
Marrero JA J Hepatol 2005; 42: 218–224 United States 70 44 26 7.1 51.4 0.0 41.4
Davila JA Gastroenterology 2004; 127: 1372–1380 United States 2584 1721 863 5.8 13.3 2.9 77.9
Ding X
c Jpn J Inf Dis 2003; 56: 19–22 United States 65 41 24 15.4 41.5 3.1 40.0
Hassan MM Hepatology 2002; 36: 1206–1213 United States 115 87 28 11.3 19.1 3.5 66.1
Abe K Hepatology 1998; 28: 568–572 United States 65 40 25 10.8 41.5 1.5 46.2
Yu MC Hepatology 1997; 25: 226–228 United States 111 67 44 7.2 31.5 1.8 59.5
Nomura A J Infect Dis 1996; 173: 1474–1476 United States 24 24 0 62.5 0.0 0.0 37.5
Di Bisceglie Am J Gastroenterol 2003; 98: 2060–2063 United States 691 — — 15.5 46.6 4.8 33.1
Di Bisceglie
a Am J Gastroenterol 1991; 86: 335–338 United States 99 67 32 6.1 12.1 1.0 80.8
Hasan F
a Hepatology 1990, 12: 589–591 United States 87 — — 27.6 35.6 4.6 32.2
Continent subtotal 3911 8.8 21.9 3.1 66.1
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Cases Prevalence (%)
First author Reference Country Total Male Female HBsAg
+ Anti-HCV
+
HBsAg
+
Anti-HCV
+
HBsAg
 
anti HCV
 
LATIN AMERICA
Miranda EC Rev Soc Bras Med Trop 2004;
37 (Suppl 2): 47–51
Brazil 36 31 5 58.3 0.0 8.3 33.3
Goncalves CS Rev Inst Med Trop Sao Paulo 1997;
39: 165–170
Brazil 180 139 41 32.8 21.1 3.9 42.2
Mondragon Sanchez R Hepatogastroenterology 2005;
52: 1159–1162
Mexico 71 — — 8.5 60.6 14.1 16.9
Ruiz E Rev Gastroenterol Peru 1998;
18: 199–212
Peru 136 116 20 63.2 0.7 0.0 36.0
Continent subtotal 423 40.7 19.4 4.7 35.2
OCEANA
Yip D
b World J Gastroenterol 1999; 5: 483–487 Australia 63 43 20 28.6 3.2 4.8 63.5
Total 30763 38.3 29.7 7.0 25.0
aStudies reporting first generation ELISA.
bStudies presumed to have used first-generation ELISA.
cStudies reporting only HCV RNA testing.
dData has been expanded since
original publication.
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